MedPath

Study of the superiority of Complete Nutrition Meals in hypertensive patients.

Not Applicable
Conditions
Essential Hypertension
Registration Number
JPRN-UMIN000047147
Lead Sponsor
EP Mediate Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Subjects who cannot continuously ingest research foods due to business trips etc. during the intake period. (2) Subjects with concomitant diabetes mellitus (However, subjects whose HbA1c is stable at less than 7% may participate in the study). (3) Subjects with severe hepatic impairment (ALT value exceeding 3 times the upper limit of the reference value), subjects with renal impairment (eGFR less than 45mL/min/1.73m2). (4) Subjects who self-reported a weight change of 5% or more within 3 months before the pre-examination. (5) Subjects with a history of myocardial infarction or stroke within the past year. (6) Subjects who are planning to change, add new or discontinue the treatment method for hypertension between the pre-examination and the intake start examination. (7) Subjects with food allergies. (8) Subjects with an average daily alcohol intake of more than 60 g. (9) Subjects with a smoking habit of more than 21 cigarettes per day. (10) Subjects who are judged by the principal investigator to be at risk of being hospitalized or having dietary restrictions etc. that may affect the continuation of the study or the intake of the research foods. (11) Subjects with diseases that may turn into serious adverse events during the study period, such as cancer. (12) Subjects who cannot properly store and ingest research foods due to reasons such as the inability to install a freezer to distribute and the lack of a microwave oven. (13) Subjects who cannot record diary or answer questionnaires on the Web. (14) Subjects with implantable medical devices such as cardiac pacemakers or life-sustaining medical devices such as biometric monitors. (15) Subjects who are planning to become pregnant or breastfeed during the study period. (16) Subjects who are participating in other clinical studies at the start of this study. (17) Subjects who are judged as unsuitable for the study by the investigator for other reason.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinic blood pressure Evaluate before ingestion, 6 weeks and 12 weeks after ingestion.
Secondary Outcome Measures
NameTimeMethod
Home blood pressure (morning, night) Therapeutic intensity score Number of drug types Physical measurement (body weight, BMI, abdominal circumference) Body-fat percentage QOL examination Fasting clinical examination Evaluate before ingestion, 6 weeks and 12 weeks after ingestion.
© Copyright 2025. All Rights Reserved by MedPath